‘Striking the Right Balance’ in Targeting PPARγ in the Metabolic Syndrome: Novel Insights from Human Genetic Studies
2007
Targeting PPARγ in Metabolic Syndrome
publication
Evidence: moderate
Author Information
Author(s): Mark Gurnell
Primary Institution: University of Cambridge
Hypothesis
Can selective PPARγ modulators improve metabolic dysfunction without causing weight gain?
Conclusion
The study suggests that understanding genetic variations in PPARγ can lead to better-targeted therapies for metabolic syndrome.
Supporting Evidence
- PPARγ is a key therapeutic target for treating metabolic diseases.
- Thiazolidinediones (TZDs) improve insulin sensitivity but can cause weight gain.
- Genetic variations in PPARγ can influence metabolic health outcomes.
Takeaway
This research looks at how a specific protein, PPARγ, can help treat obesity and diabetes without making people gain weight.
Methodology
The paper reviews clinical and laboratory observations from human genetic studies related to PPARγ.
Limitations
The study primarily focuses on genetic insights and may not cover all aspects of PPARγ modulation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website